10.6084/m9.figshare.5558575.v1 Sohda M. Sohda M. Miyazaki T. Miyazaki T. Honjyo H. Honjyo H. Hara K. Hara K. Ozawa D. Ozawa D. Sakai M. Sakai M. Yokobori T. Yokobori T. Higuchi T. Higuchi T. Tsushima Y. Tsushima Y. Kuwano H. Kuwano H. Supplementary Material for: 18F-FAMT PET Is Useful to Distinguish between Specific Uptake and Nonspecific Uptake Compared to 18F-Flourodeoxyglucose Position Emission Tomography in Esophageal Cancer Patients Karger Publishers 2017 18F-FAMT PET 18F-flourodeoxyglucose position emission tomography Specific uptake Nonspecific uptake Esophageal cancer 2017-11-01 10:03:24 Journal contribution https://karger.figshare.com/articles/journal_contribution/Supplementary_Material_for_18F-FAMT_PET_Is_Useful_to_Distinguish_between_Specific_Uptake_and_Nonspecific_Uptake_Compared_to_18F-Flourodeoxyglucose_Position_Emission_Tomography_in_Esophageal_Cancer_Patients/5558575 <p><b><i>Background:</i></b> L-[3-<sup>18</sup>F]-α-methyltyrosine (<sup>18</sup>F-FAMT) solely accumulates in tumor cells via an amino acid transport system. This selective uptake pattern results in a very high tumor-to-background ratio, enabling clear delineation of the tumor. The purpose of the present study was to assess the significance of <sup>18</sup>F-FAMT PET, which shows little nonspecific uptake compared to <sup>18</sup>F-flourodeoxyglucose position emission tomography (FDG PET) in esophageal cancer patients. <b><i>Methodology:</i></b> PET-CT studies with <sup>18</sup>F-FAMT and <sup>18</sup>F-FDG were performed as part of pretreatment work-up in 82 patients with histologically confirmed esophageal cancer. We evaluated nonspecific uptakes of <sup>18</sup>F-FDG and <sup>18</sup>F-FAMT PET. <b><i>Results:</i></b> The nonspecific uptake of <sup>18</sup>F-FAMT PET was lower than that of <sup>18</sup>F-FDG PET (<i>p = </i>0.282). In the operation group, 26.1% demonstrated nonspecific uptake in <sup>18</sup>F-FDG PET, whereas only 2.38% (1 case) demonstrated nonspecific uptake in <sup>18</sup>F-FAMT PET (<i>p = </i>0.433). In the inoperable group, 47.5% showed nonspecific uptake in <sup>18</sup>F-FDG PET, whereas 5.0% showed nonspecific uptake in <sup>18</sup>F-FAMT PET (<i>p = </i>0.079). <b><i>Conclusion:</i></b> A crucial point for the diagnostic value of PET is distinguishing specific and nonspecific uptake. <sup>18</sup>F-FAMT-PET is a very superior modality with regard to the lower rate of nonspecific uptake in esophageal cancer.</p>